Previous 10 | Next 10 |
2023-12-29 03:55:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-16 04:30:00 ET Summary The Russell 2000 is experiencing an earnings recession, with negative growth expected to continue into Q4. Q3 earnings season saw a positive surprise, with blended earnings growth improving by 430 bps to -9.9% y/y. Earnings and revenue momentum l...
2023-12-13 17:41:15 ET More on Vir Biotechnology Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript Vir Biotechnology: A Beaten Up Biotech With A Large Margin Of Saf...
– Reinforcing strategic focus on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology – – Reducing workforce by approximately 12% and consolidating geographic footprint...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, will present at the J.P. Morgan 2024 42 nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET. A live webcast of t...
2023-11-30 06:10:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the pot...
– Initial SOLSTICE data suggests the potential of VIR-3434 + VIR-2218 to address the unmet need for a highly efficacious hepatitis delta therapy – – New MARCH Part B data demonstrate that VIR-3434 may play an important role in achieving a functional cure for chronic h...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for...
2023-11-08 11:27:49 ET Summary VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since. A new BARDA contract to develop a COVID antibody and another drug against a pathogen with pandemic potential has failed to li...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500 ™ , a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. This i...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...